PHIO PHARMACEUTICALS CORP

Patricia A. Bradford’s recent insider buy at Phio Pharmaceuticals signals confidence in the company’s oncology pipeline, hinting at future upside amid a quiet market.

PHIO Pharma insider sale: CEO’s tax‑related sell keeps control steady, while PH‑762 Phase 2b milestone signals potential upside for long‑term investors.

PHIO insiders buying shares signals optimism amid volatile biotech rally—investors see confidence in undervalued cancer‑immunotherapy stock.

Insider buying at PHIO Pharmaceuticals shows CEO Robert Bitterman’s confidence, signaling potential upside amid volatile biotech market conditions.

Phio Pharmaceuticals’ insider buying surge shows executive confidence amid steep share drops; RSU conversions hint at a long‑term rebound potential.